NASDAQ:ALPN - Alpine Immune Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.51 -0.24 (-4.17 %)
(As of 01/17/2019 11:19 AM ET)
Previous Close$5.75
Today's Range$5.51 - $5.64
52-Week Range$3.66 - $11.68
Volume2,829 shs
Average Volume15,726 shs
Market Capitalization$82.11 million
P/E Ratio-4.59
Dividend YieldN/A
Beta1.16
Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Receive ALPN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545

Debt

Current Ratio9.20
Quick Ratio9.20

Price-To-Earnings

Sales & Book Value

Annual Sales$1.73 million
Price / Sales44.11
Price / Cash FlowN/A
Book Value$5.68 per share
Price / Book0.97

Profitability

Net Income$-7,780,000.00
Net Margins-1,602.19%
Return on Assets-39.08%

Miscellaneous

Employees38
Market Cap$82.11 million
OptionableNot Optionable

Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions

What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences Inc (NASDAQ:ALPN) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.57) by $0.31. Alpine Immune Sciences had a negative return on equity of 43.25% and a negative net margin of 1,602.19%. View Alpine Immune Sciences' Earnings History.

When is Alpine Immune Sciences' next earnings date?

Alpine Immune Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Alpine Immune Sciences.

What price target have analysts set for ALPN?

5 Wall Street analysts have issued twelve-month price targets for Alpine Immune Sciences' shares. Their forecasts range from $12.00 to $13.00. On average, they expect Alpine Immune Sciences' share price to reach $12.80 in the next year. This suggests a possible upside of 132.3% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.

What is the consensus analysts' recommendation for Alpine Immune Sciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.

Has Alpine Immune Sciences been receiving favorable news coverage?

News headlines about ALPN stock have trended positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alpine Immune Sciences earned a daily sentiment score of 2.6 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent news coverage is very likely to have an effect on the company's share price in the near term.

Who are some of Alpine Immune Sciences' key competitors?

Who are Alpine Immune Sciences' key executives?

Alpine Immune Sciences' management team includes the folowing people:
  • Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 51)
  • Dr. Stanford Peng, Exec. VP of R&D and Chief Medical Officer (Age 48)
  • Dr. Mark J. Litton, Pres & COO (Age 51)
  • Mr. Paul Rickey, Sr. VP & CFO (Age 40)
  • Dr. Kristine Swiderek Ph.D., Sr. VP of Research

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $5.51.

How big of a company is Alpine Immune Sciences?

Alpine Immune Sciences has a market capitalization of $82.11 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.

What is Alpine Immune Sciences' official website?

The official website for Alpine Immune Sciences is http://www.nivalis.com.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]


MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  253 (Vote Outperform)
Underperform Votes:  258 (Vote Underperform)
Total Votes:  511
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Featured Article: Dividend Aristocrat Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel